News
Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...
The Rutgers Institute for Corporate Social Innovation recognized leaders who demonstrate the potential for business to ...
We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...
StockStory.org on MSN3h
HIMS Q1 Earnings Call: Personalized Care and New Partnerships Drive Upside, Guidance Signals Near-Term TransitionTelehealth company Hims & Hers Health (NYSE:HIMS) announced in Q1 CY2025, with sales up 111% year on year to $586 million.
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...
4h
MarketBeat on MSNIs Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...
A recent study from ixlayer indicates patients are looking for pharma companies to do more to improve upon their current DTC offerings.
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.
Shares of Eli Lilly (LLY -2.90%) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results